中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2011年
13期
24-25
,共2页
钬激光%经尿道膀胱肿瘤电切术%浅表性膀胱肿瘤%复发
鈥激光%經尿道膀胱腫瘤電切術%淺錶性膀胱腫瘤%複髮
화격광%경뇨도방광종류전절술%천표성방광종류%복발
Holmium laser%Transurethral resection of bladder tumor%Superficial bladder cancer%Recurrences
目的 比较经尿道钬激光和电切术治疗浅表性膀胱癌的疗效.方法 将112例浅表性膀胱癌患者根据治疗方法分为HOLBT(钬激光膀胱肿瘤切除术)组90例和TURBT(经尿道膀胱肿瘤电切术)组22例,比较两组术中、术后情况.结果 HOLBT组术中膀胱穿孔的发生率、术后留置尿管天数、住院天数及术后尿路感染的发生率明显低于TURBT组,但两组的平均手术时间、术中输血及术后尿路狭窄的发生率比较差异无统计学意义;HOLBT组与TURBT组术后2年复发率比较差异无统计学意义,但HOLBT组术后5年复发率明显低于TURBT组.结论 钬激光是一种理想的治疗浅表性膀胱肿瘤的方法,其术中及术后并发症少,术后恢复时间较短,复发率低.
目的 比較經尿道鈥激光和電切術治療淺錶性膀胱癌的療效.方法 將112例淺錶性膀胱癌患者根據治療方法分為HOLBT(鈥激光膀胱腫瘤切除術)組90例和TURBT(經尿道膀胱腫瘤電切術)組22例,比較兩組術中、術後情況.結果 HOLBT組術中膀胱穿孔的髮生率、術後留置尿管天數、住院天數及術後尿路感染的髮生率明顯低于TURBT組,但兩組的平均手術時間、術中輸血及術後尿路狹窄的髮生率比較差異無統計學意義;HOLBT組與TURBT組術後2年複髮率比較差異無統計學意義,但HOLBT組術後5年複髮率明顯低于TURBT組.結論 鈥激光是一種理想的治療淺錶性膀胱腫瘤的方法,其術中及術後併髮癥少,術後恢複時間較短,複髮率低.
목적 비교경뇨도화격광화전절술치료천표성방광암적료효.방법 장112례천표성방광암환자근거치료방법분위HOLBT(화격광방광종류절제술)조90례화TURBT(경뇨도방광종류전절술)조22례,비교량조술중、술후정황.결과 HOLBT조술중방광천공적발생솔、술후류치뇨관천수、주원천수급술후뇨로감염적발생솔명현저우TURBT조,단량조적평균수술시간、술중수혈급술후뇨로협착적발생솔비교차이무통계학의의;HOLBT조여TURBT조술후2년복발솔비교차이무통계학의의,단HOLBT조술후5년복발솔명현저우TURBT조.결론 화격광시일충이상적치료천표성방광종류적방법,기술중급술후병발증소,술후회복시간교단,복발솔저.
Objective To compare the therapeutic effect between holmium laser and standard transurethral resection on superficial bladder cancer. Methods One hundred and twelve patients were divided into holmium laser resection of bladder cancer (HOLBT) group 90 cases and transurethral resection of bladder tumor (TURBT) group 22 cases, according to surgical procedure. The intraoperatvie and postoperative status were compared between both groups. Results The vesical perforation rate, numbers of blood transfusion, catheterization time, hospital stay and urinary tract infection rate were significantly lower in HOLBT group than that in TURBT group. There was no difference in mean operative time, blood transfusion and urinary tract stenosis between the two groups. The 5-year recurrence rate was lower in HOLBT group than that in TURBT group. Conclusions Holmium laser is a safe, effective alternative in treating superficial bladder cancer, which has fewer complication and recovering time, fast recovery and lower recurrence rate.
